Document Detail

The tryptophan metabolite 3-hydroxyanthranilic acid lowers plasma lipids and decreases atherosclerosis in hypercholesterolaemic mice.
MedLine Citation:
PMID:  22711758     Owner:  NLM     Status:  MEDLINE    
AIMS: Cardiovascular disease is the most common cause of death in the world and atherosclerosis, an inflammatory process in the vessel wall, accounts for the majority of these deaths. The tryptophan metabolite 3-hydroxyanthranilic acid (3-HAA) has been shown to inhibit inflammation in different experimental autoimmune disease models. However, the effect of 3-HAA in atherosclerosis has never been explored.
METHODS AND RESULTS: In this study, we used the atherosclerosis prone Ldlr-/- mice, and cell culture experiments to evaluate the role of 3-HAA in atherosclerosis. Eight weeks treatment with 3-HAA significantly reduced the lesion size in the aorta, and modulated local and systemic inflammatory responses. 3-hydroxyanthranilic acid inhibited the uptake of oxLDL by macrophages, an initiating event in the formation of foam cells, a major cellular component of atherosclerotic lesions. Surprisingly, 3-HAA significantly affected plasma cholesterol and triglyceride levels in Ldlr-/- mice, likely due to modulation of signalling through peroxisome proliferator-activated receptors.
CONCLUSION: 3-Hydroxyanthranilic acid inhibits atherosclerosis by regulating lipid metabolism and inflammation, two major components of this disease.
Lei Zhang; Olga Ovchinnikova; Andreas Jönsson; Anna M Lundberg; Martin Berg; Göran K Hansson; Daniel F J Ketelhuth
Related Documents :
9399358 - Glycosaminoglycan analysis in amniotic fluid and in cultured fibroblasts from normal an...
22306318 - Oit3 deficiency impairs uric acid reabsorption in renal tubule.
17988128 - Surprisingly high stability of collagen abc heterotrimer: evaluation of side chain char...
1123348 - Biosynthesis of dermatan sulfate. i. formation of l-iduronic acid residues.
23954678 - Protective effect of serofendic acid, administered intravenously, on cerebral ischemia-...
13949488 - Biosynthesis of chloramphenicol. iv. incorporation of carbon 14-labled precursors.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2012-06-18
Journal Detail:
Title:  European heart journal     Volume:  33     ISSN:  1522-9645     ISO Abbreviation:  Eur. Heart J.     Publication Date:  2012 Aug 
Date Detail:
Created Date:  2012-08-15     Completed Date:  2012-12-14     Revised Date:  2013-04-16    
Medline Journal Info:
Nlm Unique ID:  8006263     Medline TA:  Eur Heart J     Country:  England    
Other Details:
Languages:  eng     Pagination:  2025-34     Citation Subset:  IM    
Department of Medicine, Center for Molecular Medicine, L8:03, Karolinska University Hospital, Karolinska Institute, Stockholm SE-17176, Sweden.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
3-Hydroxyanthranilic Acid / pharmacology*
Atherosclerosis / immunology,  prevention & control*
Diet, High-Fat
Free Radical Scavengers / pharmacology*
Hypercholesterolemia / immunology,  prevention & control*
Hypolipidemic Agents / pharmacology
Immunity, Cellular / drug effects
Indoleamine-Pyrrole 2,3,-Dioxygenase / metabolism
Lipoproteins, LDL / drug effects,  metabolism
Macrophages / drug effects,  metabolism
Mice, Inbred Strains
RNA, Messenger / metabolism
Reg. No./Substance:
0/Free Radical Scavengers; 0/Hypolipidemic Agents; 0/Indoleamine-Pyrrole 2,3,-Dioxygenase; 0/Lipoproteins, LDL; 0/RNA, Messenger; 0/oxidized low density lipoprotein; 548-93-6/3-Hydroxyanthranilic Acid

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Do observational studies using propensity score methods agree with randomized trials? A systematic c...
Next Document:  A longer interval without growth hormone replacement and female gender are associated with lower bon...